NCT04661449

Brief Summary

Large-for-gestational-age (LGA) infants have a higher risk of metabolic disease later in life, and their postnatal growth in early childhood may be associated with long-term adverse outcomes. The purpose of this study is to explore whether comprehensive lifestyle intervention in the first year after birth in LGA infants will reduce the rate of overweight/obesity at childhood and improve neurodevelopmental outcomes and its possible mechanism.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
138

participants targeted

Target at P50-P75 for not_applicable

Timeline
44mo left

Started Jan 2021

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress60%
Jan 2021Nov 2029

First Submitted

Initial submission to the registry

November 1, 2020

Completed
1 month until next milestone

First Posted

Study publicly available on registry

December 10, 2020

Completed
1 month until next milestone

Study Start

First participant enrolled

January 22, 2021

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2023

Completed
6 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2029

Expected
Last Updated

February 5, 2021

Status Verified

December 1, 2020

Enrollment Period

2.9 years

First QC Date

November 1, 2020

Last Update Submit

February 2, 2021

Conditions

Keywords

large for gestational age

Outcome Measures

Primary Outcomes (2)

  • Rate of overweight/obesity at 2 years old

    Weight and height will be combined to report BMI in kg/m\^2. According to the intergrowth-21st age-specific BMI standard issued in 2014, BMI ≥ 85th percentile is defined as overweight; BMI ≥ 95th percentile is defined as obesity

    at 2 years old

  • Rate of overweight/obesity at 7 years old

    Weight and height will be combined to report BMI in kg/m\^2. According to the intergrowth-21st age-specific BMI standard issued in 2014, BMI ≥ 85th percentile is defined as overweight; BMI ≥ 95th percentile is defined as obesity

    at 7 years old

Secondary Outcomes (6)

  • Neurodevelopmental assessment at 2 years old

    at 2 years old

  • Carotid intima-media thickness (CIMT) at 2 years old

    at 2 years old

  • Association of BMI at 2 years old with biomarkers in cord blood

    at 2 years old

  • Association of BMI at 7 years old with biomarkers in cord blood

    at 7 years old

  • Blood pressure at 7 years old

    at 7 years old

  • +1 more secondary outcomes

Study Arms (2)

Lifestyle Intervention

EXPERIMENTAL

every 3 months within 1 year.

Other: Comprehensive lifestyle intervention

control group

NO INTERVENTION

Regular follow-up every 6 months within 1 year.

Interventions

Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).

Lifestyle Intervention

Eligibility Criteria

Age1 Day - 1 Month
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • term
  • large-for-gestational-age infants

You may not qualify if:

  • major genetic disorder
  • congenital anomalies
  • severe digestive disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xinhua Hospital

Shanghai, Shanghai Municipality, 2000892, China

RECRUITING

MeSH Terms

Conditions

Pediatric Obesity

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: randomized controlled trial
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2020

First Posted

December 10, 2020

Study Start

January 22, 2021

Primary Completion

November 30, 2023

Study Completion (Estimated)

November 30, 2029

Last Updated

February 5, 2021

Record last verified: 2020-12

Locations